08.22.23
As we enter the therapeutic era of geographic atrophy, imaging the disease is more important than ever. How are retina specialists navigating this new clinical dynamic? Moderator Rishi P. Singh, MD, is joined by Roger A. Goldberg, MD, MBA; Mrinali Gupta, MD; and Katherine Talcott, MD, as they examine which imaging modalities are best suited for busy clinics, discuss how software can facilitate longitudinal imaging tracking, and review which imaging reports are most conducive to patient education. This episode is sponsored by ZEISS.
View full description +
Sponsored by ZEISS
Subscribe
10.10.25
New Retina Radio Journal Club w/ VBS: Time-Driven Cost Analysis of PRP: Dollars, Minutes, and Patient CareNiki Kothari, MD; Jesse Sengillo, MD; and Nicholas Farber, MD
Editorially Independent Content Supported by Genentech
10.09.25
The Nuts and Bolts of GA Therapy: The Opening SessionsCharles Wykoff, MD, PhD; with Maryam Ghiassi, MD, MHS, and Matthew Cunningham, MD
Editorially independent content, supported by an educational grant from Apellis Pharmaceuticals.
10.02.25
Keeping Patients at the Center of GA Therapy: Preserving Vision vs Restoring VisionJohn Kitchens, MD; Ferhina Ali, MD, MPH; Margaret Chang, MD, MS; and David Eichenbaum, MD
Editorially independent content, supported by Astellas Pharma.
10.02.25
Keeping Patients at the Center of GA Therapy: Dosing Schedules, AREDS Vitamins, and PhotobiomodulationJohn Kitchens, MD; Ferhina Ali, MD, MPH; Margaret Chang, MD, MS; and David Eichenbaum, MD
Editorially independent content, supported by Astellas Pharma.
10.02.25
Keeping Patients at the Center of GA Therapy: Patient Education and Setting ExpectationsJohn Kitchens, MD; Ferhina Ali, MD, MPH; Margaret Chang, MD, MS; and David Eichenbaum, MD
Editorially independent content, supported by Astellas Pharma.
10.02.25
Keeping Patients at the Center of GA Therapy: Social Impact and Early InterventionJohn Kitchens, MD; Ferhina Ali, MD, MPH; Margaret Chang, MD, MS; and David Eichenbaum, MD
Editorially independent content, supported by Astellas Pharma.
09.26.25
New Retina Radio Journal Club w/ VBS: Aflibercept 8 mg in nAMD: Outcomes After Switching From FaricimabEditorially Independent Content Supported by Genentech and Astellas.
09.04.25
ASRS '25: ReCLAIM-2 and Continuous Glucose Monitoring in NPDRDavid Lally, MD; and Ehsan Rahimy, MD
Editorially independent content, supported by Genentech
Show More